Article
Amgen's Ovarian Cancer Drug Fails to Improve OS
Trebananib combined with paclitaxel improved survival by a month compared to the placebo, from 18.3 months to 19.3 months.
said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial.
Patients given the drug, trebananib, along with a chemotherapy agent paclitaxel, experienced overall survival of 19.3 months, compared with 18.3 months for the placebo group.
Statistically significant improvement in overall survival was the secondary goal of the trial.
The trial, TRINOVA-1, is the first of three late-stage studies to evaluate safety and effectiveness of the drug in ovarian cancer patients.
The company in 2013 reported results on the main goal of trial, where patients survived longer without the disease getting worse when compared with a placebo.
Link to the complete press release: http://reut.rs/10rAZC6
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
